Abstract:Down syndrome (DS) is the most example of aneuploidy, resulting from an additional copy of all or part of chromosome 21. Competing endogenous RNAs (ceRNAs) play important roles in neuronal development and neurological defects. This study aimed to identify hub genes and synergistic crosstalk among ceRNAs in the DS fetal hippocampus as potential targets for the treatment of DS-related neurodegenerative diseases. We profiled differentially expressed long non-coding RNAs (DElncRNAs), differentially expressed circular RNAs (DEcircRNAs), differentially expressed microRNAs (DEmiRNAs), and differentially expressed messenger RNAs (DEmRNAs) in hippocampal samples from patients with or without DS. Functional enrichment analysis and gene set enrichment analysis were performed, and chromosome 21-related ceRNA and protein–protein interaction networks were constructed. Additionally, the correlations between lncRNA-mRNA and miRNA-mRNA expression in the samples and HEK293T cells were validated. Our finding of changes in the expression of some key genes and ncRNAs on chromosome 21 in DS might not fully conform to the gene dosage hypothesis. Moreover, we found that four lncRNAs ( MIR99AHG , PLCB4 , SNHG14 , GIGYF2 ) and one circRNA ( hsa_circ_0061697 ) may competitively bind with three miRNAs ( hsa-miR-548b-5p , miR-730-5p , and hsa-miR-548i ) and subsequently regulate five mRNAs ( beta-1,3-galactosyltransferase 5 [ B3GALT5 ], helicase lymphoid-specific [ HELLS ], thrombospondin-2 [ THBS2 ], glycinamide ribonucleotide transformylase [ GART ], clathrin heavy chain like 1 [ CLTCL1 ]). These RNAs, whether located on chromosome 21 or not, interact with each other and might activate the PI3K/Akt/mTOR and Wnt signaling pathways, which are involved in autophagosome formation and tau hyperphosphorylation, possibly leading to adverse consequences of trisomy 21. These findings provide researchers with a better understanding of the fundamental molecular mechanisms underlying DS-related progressive defects in neuronal development.

Abnormal mitochondria in Down syndrome iPSC-derived GABAergic interneurons and organoids

Modeling Down Syndrome with Patient iPSCs Reveals Cellular and Migration Deficits of GABAergic Neurons

DSCAM/PAK1 pathway suppression reverses neurogenesis deficits in iPSC-derived cerebral organoids from patients with Down syndrome

STEM CELLS ® EMBRYONIC STEM CELLS / INDUCED PLURIPOTENT STEM CELLS Induced Pluripotent Stem Cells with a Pathological Mitochondrial DNA Deletion

Induced Pluripotent Stem Cells with a Mitochondrial DNA Deletion.

The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model

RUNX1 Upregulation Causes Mitochondrial Dysfunction Via Regulating the PI3K-Akt Pathway in Ipsc from Patients with Down Syndrome

Single-cell RNA Sequencing of Neural Stem Cells Derived from Human Trisomic Ipscs Reveals the Abnormalities During Neural Differentiation of Down Syndrome.

DSCAM gene triplication causes excessive GABAergic synapses in the neocortex in Down syndrome mouse models

Value of Cytopathologist‐performed Ultrasound‐guided Fine‐needle Aspiration As a Screening Test for Ultrasound‐guided Core‐needle Biopsy in Nonpalpable Breast Masses

Realizing the Potential of Exploiting Human IPSCs and Their Derivatives in Research of Down Syndrome

Genome‐wide hypermethylation is closely associated with abnormal expression of genes involved in neural development in induced pluripotent stem cells derived from a Down syndrome mouse model

Abnormal MicroRNA Expression in Ts65Dn Hippocampus and Whole Blood: Contributions to Down Syndrome Phenotypes

Single-nucleus RNA sequencing reveals cell type-specific transcriptome alterations of Down syndrome hippocampus using the Dp16 mouse model

Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination

Competing Endogenous RNAs Crosstalk in Hippocampus: A Potential Mechanism for Neuronal Developing Defects in Down Syndrome

Single‐cell landscape analysis reveals systematic senescence in mammalian Down syndrome

Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions

Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome

The Study of Alternative Splicing Events in Human Induced Pluripotent Stem Cells From a Down's Syndrome Patient

Type I Interferon Signaling Drives Microglial Dysfunction and Senescence in Human iPSC Models of Down Syndrome and Alzheimer’s Disease